Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00638807
Recruitment Status : Completed
First Posted : March 19, 2008
Last Update Posted : March 13, 2009
Information provided by:

Brief Summary:
To compare the efficacy and safety of celecoxib versus placebo for the treatment of knee osteoarthritis (OA) in patients who were unresponsive to prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: Celecoxib Other: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 388 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen
Study Start Date : December 2003
Actual Study Completion Date : July 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Arm Intervention/treatment
Experimental: A Drug: Celecoxib
200 mg oral capsule once daily with morning meal for 6 weeks
Placebo Comparator: B Other: Placebo
Matched oral placebo for 6 weeks

Primary Outcome Measures :
  1. Change from baseline in Patient's Assessment of Arthritis Pain, according to visual analog scale (VAS) [ Time Frame: Week 6 ]

Secondary Outcome Measures :
  1. Patient's Assessment of Arthritis Pain, according to VAS [ Time Frame: Week 2 ]
  2. The Western Ontario and McMaster Universities Osteoarthritis Index [ Time Frame: Week 6 ]
  3. Patient's and Physician's Global Assessment of Arthritis [ Time Frame: Weeks 2 and 6 ]
  4. The Medical Outcomes Study Sleep Scale [ Time Frame: Week 6 ]
  5. Adverse events [ Time Frame: Weeks 0-6 ]
  6. Laboratory tests [ Time Frame: Week 6 ]
  7. Vital signs [ Time Frame: Week 6 ]
  8. Physical examination [ Time Frame: Week 6 ]
  9. Serious adverse events [ Time Frame: Up to 30 days after last dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Inclusion criteria:

  • Diagnosed, active, and symptomatic OA of the knee in a flare state with a functional capacity class of I-III at baseline visit
  • Failed adequate trials of both naproxen and ibuprofen (prescription strength) within the past 5 years due to lack of efficacy, tolerability, or both; duration of prescription strength ibuprofen and naproxen must have been a minimum of 2 weeks for each drug at the respective recommended doses if failure was due to lack of efficacy, and for any duration if failure was due to lack of tolerability

Exclusion Criteria:

Exclusion criteria:

  • Inflammatory arthritis or gout/pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Received acetaminophen within 24 hours of the baseline visit
  • Use of a mobility assisting device for less than six weeks prior to study screening or use of a walker
  • History of gastrointestinal (GI) perforation, obstruction, or bleeding
  • Diagnosed or treated for GI ulcer within 60 days prior to first dose of study medication
  • Received corticosteroids or hyaluronic acid within certain timeframe before study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00638807

  Hide Study Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35235
United States, California
Pfizer Investigational Site
Buena Park, California, United States, 90620
United States, Colorado
Pfizer Investigational Site
Denver, Colorado, United States, 80204
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20006
United States, Florida
Pfizer Investigational Site
Longwood, Florida, United States, 32779
Pfizer Investigational Site
Miami, Florida, United States, 33186
Pfizer Investigational Site
Zephyrhills, Florida, United States, 33540
United States, Idaho
Pfizer Investigational Site
Boise, Idaho, United States, 83704
Pfizer Investigational Site
Boise, Idaho, United States, 83706
United States, Illinois
Pfizer Investigational Site
Morton Grove, Illinois, United States, 60053
United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67206
Pfizer Investigational Site
Wichita, Kansas, United States, 67214
United States, Maryland
Pfizer Investigational Site
Wheaton, Maryland, United States, 20902
United States, Missouri
Pfizer Investigational Site
Springfield, Missouri, United States, 65807
United States, Montana
Pfizer Investigational Site
Bozeman, Montana, United States, 59715
United States, New Jersey
Pfizer Investigational Site
Trenton, New Jersey, United States, 08611
United States, New York
Pfizer Investigational Site
Binghamton, New York, United States, 13901
Pfizer Investigational Site
Brooklyn, New York, United States, 11203
Pfizer Investigational Site
New York, New York, United States, 10022-1009
United States, North Carolina
Pfizer Investigational Site
Cary, North Carolina, United States, 27609
Pfizer Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
Pfizer Investigational Site
Bismarck, North Dakota, United States, 58506
United States, Oregon
Pfizer Investigational Site
Eugene, Oregon, United States, 97401
Pfizer Investigational Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635-0909
Pfizer Investigational Site
Johnstown, Pennsylvania, United States, 15904
United States, Rhode Island
Pfizer Investigational Site
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29407
United States, Tennessee
Pfizer Investigational Site
New Tazewell, Tennessee, United States, 37825
United States, Texas
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Virginia
Pfizer Investigational Site
Arlington, Virginia, United States, 22203
Pfizer Investigational Site
Norfolk, Virginia, United States, 23502
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98166
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc Identifier: NCT00638807     History of Changes
Other Study ID Numbers: A3191082
First Posted: March 19, 2008    Key Record Dates
Last Update Posted: March 13, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase 2 Inhibitors
Gout Suppressants